PF-04971729
A potent and selective SGLT2 inhibitor with IC50 of 0.877 nM for hSGLT2; shows >2000-fold selectivity over hSGLT1; demonstrates robust urinary glucose excretion in rats and an excellent preclinical safety profile.Diabetes Phase 3 Clinical (In Vitro) :Ertugliflozin (PF-04971729) demonstrates >2000-fold selectivity for SGLT2 inhibition (relative to SGLT1) in vitro. (In Vivo) :Ertugliflozin (PF-04971729) reveals a concentration-dependent glucosuria after oral administration to rats.
Product Specifications
CAS Number
1210344-57-2
Product Name Alternative
Ertugliflozin | MK-8835 | PF-4971729
Purity
>98% (HPLC)
Solubility
DMSO: ≥ 46 mg/mL
Smiles
O[C@@H]1[C@] (O2) (CO) CO[C@]2 (C3=CC=C (Cl) C (CC4=CC=C (C=C4) OCC) =C3) [C@H] (O) [C@H]1O
Molecular Formula
C22H25ClO7
Molecular Weight
436.8827
Storage Conditions
Storage temperature: -20°C. Stability: ≥ 2 years
Notes
For research use only.
Other Product Names
β-L-Idopyranose, 1,6-anhydro-1-C-[4-chloro-3-[ (4-ethoxyphenyl) methyl]phenyl]-5-C- (hydroxymethyl) -
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
![Anti-Unknown Specificity (Isotype control) [MOPC-21]](https://cdn.genprice.uk/genprice/uk/genprice5.webp)
Anti-Unknown Specificity (Isotype control) [MOPC-21]
Recombinant Polaromonas sp. 1-deoxy-D-xylulose-5-phosphate synthase (dxs), partial
PE-Linked Polyclonal Antibody to Annexin A5 (ANXA5)